Effect of Diabetes and Glycemic Control on Ischemic Stroke Risk in AF Patients ATRIA Study by Ashburner, Jeffrey M. et al.
Listen to this manuscript’s
audio summary by
JACC Editor-in-Chief
Dr. Valentin Fuster.
J O U R N A L O F T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y V O L . 6 7 , N O . 3 , 2 0 1 6
ª 2 0 1 6 B Y T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y F O UN DA T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 5 . 1 0 . 0 8 0ORIGINAL INVESTIGATIONSEffect of Diabetes and Glycemic Control
on Ischemic Stroke Risk in AF Patients
ATRIA StudyJeffrey M. Ashburner, PHD, MPH,*yz Alan S. Go, MD,xk{ Yuchiao Chang, PHD,*y Margaret C. Fang, MD, MPH,#
Lisa Fredman, PHD, MSPH,z Katie M. Applebaum, SCD, MSPH,**yy Daniel E. Singer, MD*yABSTRACTFro
Sch
xD
an
Sch
for
Wa
Bo
Na
Ma
tat
con
JohBACKGROUND Diagnosed diabetes mellitus (DM) is a consistently documented risk factor for ischemic stroke in
patients with atrial ﬁbrillation (AF).
OBJECTIVES The purpose of this study was to assess the association between duration of diabetes and elevated
hemoglobin A1c (HbA1c) with risk of stroke among diabetic patients with AF.
METHODS We assessed this association in the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) California
community-based cohort of AF patients (study years 1996 to 2003) where all events were clinician adjudicated. We used
Cox proportional hazards regression to estimate the rate of ischemic stroke in diabetic patients according to time-varying
measures of estimated duration of diabetes ($3 years compared with <3 years) and HbA1c values ($9.0% and 7.0% to
8.9% compared with <7.0%), focusing on periods where patients were not anticoagulated.
RESULTS There were 2,101 diabetic patients included in the duration analysis: 40% with duration <3 years and
60% with duration $3 years at baseline. Among 1,933 diabetic patients included in the HbA1c analysis, 46% had
HbA1c<7.0%, 36% between 7.0% and 8.9%, and 19%$9.0% at baseline. Duration of diabetes$3 years was associated
with an increased rate of ischemic stroke compared with duration <3 years (adjusted hazard ratio [HR]: 1.74, 95%
conﬁdence interval [CI]: 1.10 to 2.76). The increased stroke rate was observed in older (age $75 years) and younger
(age <75 years) individuals. Neither poor glycemic control (HbA1c $9.0%, adjusted HR: 1.04, 95% CI: 0.57 to 1.92) nor
moderately increased HbA1c (7.0% to 8.9%, adjusted HR: 1.21, 95% CI: 0.77 to 1.91) were signiﬁcantly associated with an
increased rate of ischemic stroke compared with patients who had HbA1c <7.0%.
CONCLUSIONS Duration of diabetes is a more important predictor of ischemic stroke than glycemic control in patients
who have diabetes and AF. (J Am Coll Cardiol 2016;67:239–47)
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240A trial ﬁbrillation (AF) is the mostcommon clinically signiﬁcant ar-rhythmia and is associated with a
4- to 5-fold increase in the risk for ischemic
stroke (1,2). Roughly 15% of patients with
AF also carry the diagnosis of diabetes (3,4).
Diagnosed diabetes mellitus (DM) is a consis-
tently documented risk factor for ischemic
stroke in patients with AF (5,6). A diagnosis
of DM is included in the CHADS2 (congestiveheart failure, hypertension, age, diabetes, prior
stroke) and CHA2DS2-VASc (congestive heart failure,
hypertension, age $75 years, diabetes mellitus,
stroke/transient ischemic attack, vascular disease,
age 65 to 74 years, sex category) stroke risk scoring
systems for AF patients that are widely used to guide
decision making for anticoagulation therapy (7,8).
However, it is unclear which aspects of diabetes,
including duration and glycemic control, may be
associated with an increased risk of stroke in AF pa-
tients as prior studies have only assessed the diag-
nosis of DM as a risk factor (5,6).SEE PAGE 248The association between duration of diabetes and
ischemic stroke risk has recently been studied in a
general population of patients, with longer duration
of diabetes associated with increased risk of stroke
compared with nondiabetic patients (9,10). The
association between hemoglobin A1c (HbA1c), a
measure of glycemia during the prior 3 months, and
ischemic stroke among DM patients has been inves-
tigated in general populations (11–13). Elevated HbA1c
at baseline was an independent risk factor for stroke
in DM patients with risk ratios of 1.17 and 2.33 for the
highest 2 tertiles of HbA1c compared with the lowest
tertile over 10 years of follow-up (12). Despite evi-
dence for an association between elevated HbA1c and
duration of diabetes with risk of stroke among dia-
betic patients in general, predominantly in non-AF
populations, it is unknown whether there is an asso-
ciation among diabetic patients with AF because the
pathophysiology of stroke may be different in these
populations.
To address these knowledge gaps, we aimed to
assess the association between duration of diabetes
and glycemic control with the rate of ischemic stroke
in AF patients off anticoagulation therapy in clinicalith Medtronic, Inc., related to atrial ﬁbrillation and risk of stroke,
rillation, and with Bristol-Myers Squibb related to atrial ﬁbrillatio
ave no relationships relevant to the contents of this paper.
received October 14, 2015; accepted October 20, 2015.care within a large community-based cohort of
patients with AF and comprehensive follow-up.
METHODS
STUDY POPULATION. The ATRIA (Anticoagulation
and Risk Factors in Atrial Fibrillation) cohort has
been described in detail previously (14). In brief, the
cohort includes 13,559 adults age 18 years and older
with diagnosed nonvalvular AF who received care
within Kaiser Permanente of Northern California (3).
Cohort members were identiﬁed by searching elec-
tronic inpatient, outpatient, and electrocardiographic
databases for physician-assigned International Clas-
siﬁcation of Diseases, Ninth Revision, Clinical Modiﬁ-
cation (ICD-9-CM) diagnostic codes of AF (427.31,
427.32) between July 1996 and December 1997. We
included all patients age $18 years with either $2
outpatient AF diagnoses or 1 outpatient AF diagnosis
with electrocardiogram validation. Included patients
were followed through September 2003. Because
we were interested in nontransient, nonvalvular
AF, we excluded AF patients with diagnosed mitral
stenosis, valvular repair or replacement, transient
post-operative AF, or concurrent hyperthyroidism.
We focused these analyses on patients with diag-
nosed diabetes mellitus at baseline or who were
diagnosed during follow-up. The presence of dia-
betes mellitus was assessed from a validated longi-
tudinal regional health plan diabetes registry (1,15),
which used relevant inpatient and outpatient
diagnoses (ICD-9-CM 250.0 to 250.8), an abnormal
(>6.7%) hemoglobin A1c (HbA1c) level, or a ﬁlled
prescription for oral hypoglycemic agents or insulin
to identify patients with diabetes. The patient’s in-
dex date for these analyses was either the beginning
of follow-up in the ATRIA cohort for those with
diabetes at baseline, or the date of diabetes onset for
those diagnosed with diabetes during follow-up in
the ATRIA cohort.
MEASURES. Exposures . Duration of diabetes was
assigned both according to duration at baseline and as
a time-varying exposure and was categorized as
<3 years and $3 years. An a priori 3-level categoriza-
tion was initially explored (<3, 3 to 8, and >8 years),
but the longer duration categories were collapsed
due to similar effect sizes (Online Table 1). For anal-
yses among diabetic patients, duration <3 years waswith Johnson & Johnson related to stroke prevention
n and risk of stroke. All other authors have reported
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241considered to be the reference category. We con-
ducted additional analyses where AF patients without
diabetes were considered to be the reference category.
Diabetes onset date for duration calculations was
determined either by self-report from respondents
with diabetes from the diabetes registry or by using
information on the basis of meeting the ﬁrst qualifying
criteria from diagnoses, laboratory test results, or
medications. Patients without a diabetes onset date
were excluded (n ¼ 106) from all analyses. Glycemic
control was measured with HbA1c values from the
regional health plan laboratory database on the basis
of HbA1c tests that were ordered as part of clinical
management. Both the baseline HbA1c value only as
well as HbA1c values updated over time were used.
Time-varying HbA1c values were considered valid for
up to 1-year. At baseline, we looked back over the prior
year for the most recent HbA1c value. If there was no
value during this time period, the time between
baseline and the ﬁrst HbA1c value after baseline was
excluded. If this time period between the baseline and
ﬁrst HbA1c value was longer than 1 year, then the pa-
tient was excluded from analysis (n ¼ 171). When
considering HbA1c values as time-varying, if the time
between HbA1c values during follow-up exceeded
1-year, then the time from 1-year follow-up until the
next HbA1c value was excluded. HbA1c values were
categorized at common clinical cut points: <7.0%,
7.0% to 8.9%, and $9.0%. We also performed a
sensitivity analysis regarding themissing time-varying
HbA1c values, where HbA1c values were considered
valid for only 6months or for up to 1.5 years, andwhere
values were assigned using linear interpolation be-
tween HbA1c tests.
Outcome. Ischemic stroke events were identiﬁed by
searching hospitalization and billing claims databases
for relevant ICD-9-CM codes for ischemic stroke
found in the primary discharge diagnosis position (3).
Potential events were adjudicated by a clinical out-
comes committee composed of physicians using
medical records review, with a ﬁnal decision made by
a consulting neurologist if consensus was not reached
by the committee. A valid ischemic stroke was deﬁned
as a documented acute neurological deﬁcit lasting
>24 h that was not explained by other causes (e.g.,
primary hemorrhage, trauma, infection, or vasculitis).
COVARIABLES. Pat ient character i st i cs . Data on
patient age (continuous), sex, and self-reported race/
ethnicity (white, black/African American, Asian/
Paciﬁc Islander, Hispanic ethnicity, other/unknown)
were obtained from administrative databases. Educa-
tional attainment status and income status were
assigned from geocoding on the basis of U.S. Census
block group data.Per iods off ant i coagulat ion . To examine the role
of glycemic control and duration of diabetes on risk of
ischemic stroke, we focused on periods of follow-up
off anticoagulation. To identify periods off warfarin
therapy, we used a previously validated method to
assign use of warfarin on the basis of data from pre-
scriptions and outpatient international normalized
ratio measurements found in pharmacy and labo-
ratory databases, respectively (3). Longitudinal war-
farin exposure was on the basis of number of
days of supply per prescription and intervening in-
ternational normalized ratios. For any 2 consecutive
prescriptions with a gap of up to 60 days, a patient
was considered to be continuously on warfarin. For
gaps >60 days, we considered the patient to be
continuously on warfarin if there were intervening
international normalized ratio measurements at least
every 42 days. Otherwise, the patient was considered
off warfarin from day 31 after the end date of the ﬁrst
prescription until the start date of the next prescrip-
tion. This grace period of 30 days at the end of each
warfarin period was given because changes in
warfarin dose are common.
Health- re lated var iab les . History of comorbid
conditions, including prior ischemic stroke, chronic
heart failure, coronary disease, and hypertension,
were collected from clinical inpatient and ambulatory
databases using validated algorithms, were assessed
using data during the 5 years prior to the patient’s
index date, and were updated during the follow-up
period. Kidney dysfunction (deﬁned as estimated
glomerular ﬁltration rate <45 ml/min/1.73 m2) was
calculated from laboratory values using the Chronic
Kidney Disease Epidemiology Collaboration formula
(16). Patients without an estimated glomerular
ﬁltration rate value in the prior year were considered
to have normal renal function, and patients on dial-
ysis were considered to have kidney dysfunction.
Proteinuria was deﬁned as a urine dipstick protein
result of $1þ (30 mg/dl or higher) in the absence of
potential urinary tract infection found in laboratory
databases (17). Patients without a urine dipstick
protein laboratory result in the prior year were
considered to not have proteinuria. Insulin use was
time-varying and was assessed from prescription
databases. All health-related variables were dichoto-
mized. For all patients, the CHADS2 (7), CHA2DS2-
VASc (8), and ATRIA (18) stroke risk scores were
calculated. Functional disability at the time of hos-
pital discharge was determined through review of
notes in the medical record. Disability was catego-
rized using a modiﬁed Rankin scale into fatal inpa-
tient event, major/severe disability (deﬁcits that
prevented independent living, corresponding to
TABLE 1 Characteris
Age, yrs
<65
65–74
$75
Female
Race
White
Black/African Americ
Asian/Paciﬁc Islande
Hispanic
Other/unknown
Education (less than hig
graduation)
Income (annual househ
income <$35,0
Comorbidities and diab
characteristics
Prior ischemic stroke
Chronic heart failure
Coronary disease
Peripheral arterial di
Hypertension
Proteinuria
Signiﬁcant kidney dy
Insulin use
HbA1c value, %
<7.0
7.0–8.9
$9.0
Duration of diabetes
0–3
$3
Predicted stroke risk
CHADS2
CHA2DS2-VASc
ATRIA stroke risk sco
Values are mean  SD or n
‡The p values represent co
were signiﬁcantly different
were signiﬁcantly different
ATRIA ¼ Anticoagulation
age $75 years, diabetes m
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242Rankin scores of 3 to 5), minor disability (residual
deﬁcit that did not interfere with independent living,
equivalent to Rankin scores of 1 to 2), and no
disability (Rankin score 0) (19). Assignment of
modiﬁed Rankin scores in the ATRIA study was
validated by post-hospital fatality rates (20).
STATISTICAL ANALYSES. We conducted descriptive
and stratiﬁed analyses to examine the distri-
bution of potential confounders among duration
and HbA1c categories. The associations betweentics of Diabetic Patients by Estimated Diabetes Duration and HbA1c Valu
Nondiabetic
(n ¼ 8,356)
Diabetes Duration*
0 to 3 yrs
(n ¼ 837)
$3 yrs
(n ¼ 1,264)
p
Value‡
71.8  12.7 69.0  11.0 71.7  8.9 <0.001
1,903 (22.8) 244 (29.2) 251 (19.9) <0.001
2,422 (29.0) 311 (37.2) 494 (39.1)
4,031 (48.2) 282 (33.7) 519 (41.1)
3,714 (44.5) 321 (38.4) 501 (39.6) 0.55
<0.001
7,226 (86.5) 700 (83.6) 1,071 (84.7)
an 306 (3.7) 28 (3.4) 73 (5.8)
r 416 (5.0) 75 (9.0) 74 (5.9)
193 (2.3) 23 (2.8) 43 (3.4)
215 (2.6) 11 (1.3) 3 (0.2)
h school 677 (8.1) 92 (10.9) 136 (10.7) 0.93
old
00)
907 (10.9) 98 (11.7) 160 (12.6) 0.68
etes
632 (7.6) 52 (6.2) 173 (13.7) <0.001§
2,141 (25.6) 251 (30.0) 583 (46.1) <0.001§
2,117 (25.3) 261 (31.2) 581 (46.0) <0.001§
sease 157 (1.9) 18 (2.2) 63 (5.0) 0.005§
3,852 (46.1) 497 (59.4) 901 (71.3) <0.001§
926 (11.1) 103 (12.3) 366 (29.0) <0.001§
sfunction 1,166 (14.0) 94 (11.2) 280 (22.2) <0.001§
— 38 (4.5) 490 (38.8) <0.001§
<0.001§
— 417 (49.8) 461 (36.5)
— 285 (34.1) 508 (40.2)
— 135 (16.1) 295 (23.3)
, yrs
— — —
— — —
1.4  1.1 2.4  1.1 2.9  1.2 <0.001
2.8  1.7 3.8  1.6 4.5  1.6 <0.001
re 4.9  2.8 5.5  2.7 6.8  2.6 <0.001
(%). *Population excludes n ¼ 106 without a diabetes onset date. †Population excludes n ¼
mparisons among diabetic patients (reference categories are duration #3 years and HbA1c
(p < 0.05) in all categories except for income status, peripheral arterial disease, prior ischem
in all categories except mean age. §Adjusted for age, sex, and race.
and Risk Factors in Atrial Fibrillation; CHADS2 ¼ congestive heart failure, hypertension, a
ellitus, stroke/transient ischemic attack, vascular disease, age 65 to 74 years, sex category;comorbid conditions and diabetes characteristics
with duration and HbA1c categories were adjusted
for age, sex, and race in logistic regression models
(Table 1). To construct person-time data, follow-up
began on the ﬁrst day the patient held a diagnosis
of diabetes and was not receiving warfarin therapy
and ended at the ﬁrst occurrence of any of the
following: ischemic stroke, death, disenrollment
from the health plan, or end of the follow-up period.
Additionally, follow-up was stopped if the patientes at Baseline
HbA1c†
HbA1c <7.0%
(n ¼ 883)
HbA1c 7.0% to 8.9%
(n ¼ 690)
HbA1c $9.0%
(n ¼ 360)
p
Value‡
71.5  9.6 70.5  9.7 67.9  9.8 <0.001
184 (20.8) 161 (23.3) 118 (32.8) <0.001
326 (36.9) 277 (40.1) 144 (40.0)
374 (42.4) 252 (36.5) 98 (27.2)
325 (36.8) 273 (39.6) 153 (42.5) 0.16
0.02
764 (86.5) 591 (85.7) 283 (78.6)
31 (3.5) 35 (5.1) 28 (7.8)
55 (6.2) 44 (6.4) 33 (9.2)
27 (3.1) 15 (2.2) 14 (3.9)
6 (0.7) 4 (0.6) 3 (0.8)
83 (9.4) 79 (11.5) 49 (13.6) 0.10
100 (12.0) 87 (13.4) 44 (13.0) 0.52
92 (10.4) 70 (10.1) 35 (9.7) 0.98†
342 (38.7) 264 (38.3) 146 (40.6) 0.36†
351 (39.8) 287 (41.6) 134 (37.2) 0.56†
34 (3.9) 26 (3.8) 14 (3.9) 0.86†
601 (68.1) 475 (68.8) 220 (61.1) 0.02†
185 (21.0) 146 (21.2) 91 (25.3) 0.26†
150 (17.0) 119 (17.2) 58 (16.1) 0.92†
142 (16.1) 226 (32.8) 149 (41.4) <0.001†
— — —
— — —
— — —
<0.001†
458 (51.9) 226 (32.8) 89 (24.7)
425 (48.1) 464 (67.2) 271 (75.3)
2.7  1.2 2.6  1.1 2.5  1.0 0.01
4.3  1.6 4.2  1.6 4.0  1.6 0.01
6.4  2.7 6.2  2.6 5.8  2.7 0.008
171 with initial gap >1 year and n ¼ 106 without a diabetes onset date (n ¼ 274 total).
<7%). Compared with nondiabetic patients, diabetic patients with duration #3 years
ic stroke, and signiﬁcant kidney dysfunction. Diabetic patients with duration >3 years
ge, diabetes, prior stroke; CHA2DS2-VASc ¼ congestive heart failure, hypertension,
HbA1c ¼ hemoglobin A1c.
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243initiated warfarin therapy and resumed if there was
another period without warfarin therapy. Cox pro-
portional hazards regression was used to estimate
the unadjusted and adjusted hazard ratio (HR) for
the association between HbA1c and ischemic stroke,
as well as with duration of diabetes and ischemic
stroke (SAS version 9.3, SAS Institute, Cary, North
Carolina). We constructed models that used only
baseline exposure (HbA1c or duration) values as well
as models that used time-varying exposure values.
To further assess and control for confounding, we
added race, education, income, and time-varying
CHA2DS2-VASc (which includes all of the CHADS2
risk factors) and ATRIA stroke risk score factors to
our multivariable models. For the HbA1c analysis, we
also adjusted for time-varying use of insulin and
duration of diabetes. For the duration of diabetes
analyses, we did not adjust for HbA1c, use of insulin,
proteinuria, or kidney dysfunction, because we
believed these variables to be on the causal pathway
from diabetes duration to ischemic stroke. Duration
analyses were stratiﬁed by age (<75 and $75 years).
To assess the presence of additive interaction be-
tween HbA1c and diabetes duration, we calculated
the relative excess rate due to interdependence
(RERI) (21).
This research was approved by the institutional
review boards at Massachusetts General Hospital and
at Kaiser Foundation Research Institute. A waiver of
informed consent was obtained because of the nature
of the study.
RESULTS
Among 2,101 diabetic patients included in the diabetes
duration analysis, 837 (39.8%) had estimated diabetes
duration for #3 years at baseline, whereas 1,264
(60.2%) had estimated diabetes duration for >3 years
at baseline (Table 1). The mean duration of diabetes at
baseline was 7.5  9.6 years (median 4.7 years).
Patients who had diabetes for>3 years were older than
those with diabetes for 0 to 3 years. In addition, they
were more likely to have had a prior ischemic stroke;
to have diagnosed chronic heart failure, coronary
disease, peripheral arterial disease, hypertension,
proteinuria, or signiﬁcant kidney dysfunction; to be
using insulin; and to have HbA1c $9.0% compared
with patients with duration #3 years at baseline after
adjusting for age, sex, and race. Patients with longer
duration of diabetes also had increased risk of stroke
according to CHADS2, CHA2DS2-VASc, and ATRIA
stroke risk scores.
Among 1,933 diabetic patients included in theHbA1c
analysis, 883 (45.7%) had an HbA1c value <7.0%at baseline, 690 (35.7%) had an HbA1c value between
7.0% and 8.9%, and 360 (18.6%) had an HbA1c
value $9.0% (Table 1). Patients with HbA1c $9.0%
were younger and less likely to be white. Patients with
HbA1c $9.0% also were less likely to have diagnosed
hypertension,weremore likely to be using insulin, and
had diabetes for a longer period of time compared with
patients with lower HbA1c values at baseline after
adjusting for age, sex, and race. There were small, but
statistically signiﬁcant, differences in CHADS2,
CHA2DS2-VASc, and ATRIA stroke risk scores among
HbA1c categories, with HbA1c$9.0%having the lowest
stroke risk scores.
FOLLOW-UP. In the duration of diabetes analysis,
there was 5,219.7 person-years off of warfarin therapy
included (mean 2.48  2.23 years/patient) among
diabetic patients. Nondiabetic patients contributed
25,806.7 person-years off of warfarin therapy (mean
3.09  2.48 years/patient). For both analyses, dia-
betic patients without a known diabetes onset date
were excluded, but they only represented 102.2
person-years.
There were a total of 7,217 HbA1c measurements
during follow-up. The median number of days
between HbA1c measurements was 143 (interquartile
range: 89 to 240 days), with median 154 days among
HbA1c <7.0% group, median 135 days among HbA1c
7.0% to 8.9%, and median 135 days among
HbA1c $ 9.0%. The HbA1c analysis included 3,818.0
person-years off of warfarin therapy (mean 1.98 
1.98 years/patient). Due to gaps between HbA1c
measurements that exceeded 1 year, 1,236.8 off-
warfarin person-years were excluded from analyses
with time-varying HbA1c values.
DURATION OF DIABETES AND ISCHEMIC STROKE.
During follow-up, there were 137 validated ischemic
stroke events among diabetic patients included in the
duration of diabetes analysis. The rate of ischemic
stroke during follow-up was higher among patients
with estimated duration of diabetes $3 years (2.9 per
100 person-years) compared with patients who had
an estimated duration of diabetes <3 years (1.7 per
100 person-years) (Table 2). In unadjusted analyses,
diabetes duration $3 years was associated with an
increased rate of ischemic stroke compared with
duration <3 years (unadjusted HR: 2.04, 95% conﬁ-
dence interval [CI]: 1.27 to 3.26). After adjustment for
stroke risk factors in multivariable analyses, the
increased rate of ischemic stroke associated with
diabetes duration $3 years remained elevated
(adjusted HR: 1.74, 95% CI: 1.10 to 2.76). In analyses
stratiﬁed by age (<75 and $75 years), the increased
rate of ischemic stroke in patients with duration
TABLE 3
Ischemic
Baseline H
Ischemi
Person-
Rate, pe
Hazard
Hazard
Time-vary
Ischemi
Person-
Rate, pe
Hazard
Hazard
*Adjusted f
ischemic str
dysfunction
HbA1c ¼
TABLE 2 Association Between Estimated Duration of Diabetes and Incidence of
Ischemic Stroke
Nondiabetic
Estimated Diabetes
Duration <3 yrs
Estimated Diabetes
Duration $3 yrs
Baseline duration values
Ischemic stroke events 463 44 93
Person-yrs 25,801.8 2,299.9 2,919.8
Rate, per 100 person-yrs 1.8 1.9 3.2
Among diabetic patients only
Hazard ratio (unadjusted) N/A Reference 1.75 (1.22–2.50)
Hazard ratio (adjusted*) N/A Reference 1.51 (1.05–2.17)
Among all patients
Hazard ratio (unadjusted) Reference 1.10 (0.81–1.50) 1.80 (1.44–2.25)
Hazard ratio (adjusted*) Reference 1.15 (0.84–1.58) 1.63 (1.29–2.05)
Time-varying duration values
Ischemic stroke events 463 21 116
Person-yrs 25,801.8 1,260.6 3,959.1
Rate, per 100 person-yrs 1.8 1.7 2.9
Among diabetic patients only
Hazard ratio (unadjusted) N/A Reference 2.04 (1.27–3.26)
Hazard ratio (adjusted*) N/A Reference 1.74 (1.10–2.76)
Among all patients
Hazard ratio (unadjusted) Reference 0.84 (0.55–1.30) 1.75 (1.43–2.15)
Hazard ratio (adjusted*) Reference 0.90 (0.58–1.40) 1.62 (1.31–2.00)
*Adjusted for age, sex, race, education, income, congestive heart failure, hypertension, prior ischemic stroke,
coronary artery disease, and peripheral arterial disease.
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244$3 years was present in both age groups, but was
larger in the older age group (age <75 years, baseline
duration–adjusted HR: 1.52, 95% CI: 0.92 to 2.52;
time-varying duration–adjusted HR: 1.75, 95% CI:
0.81 to 3.80; $75 years, baseline duration–adjusted
HR: 1.55, 95% CI: 0.92 to 2.62; time-varying duration–
adjusted HR: 1.71, 95% CI: 0.96 to 3.06). AdditiveAssociation Between HbA1c Values and Incidence of
Stroke
HbA1c <7.0% HbA1c 7.0%–8.9% HbA1c $9.0%
bA1c values
c stroke events 58 50 29
yrs 2,198.6 1,754.2 1,009.8
r 100 person-yrs 2.6 2.9 2.9
ratio (unadjusted) Reference 1.09 (0.75–1.60) 1.10 (0.70–1.72)
ratio (adjusted*) Reference 1.03 (0.69–1.54) 1.05 (0.66–1.66)
ing HbA1c values
c stroke events 42 46 16
yrs 1,690.8 1,545.3 581.9
r 100 person-yrs 2.5 3.0 2.7
ratio (unadjusted) Reference 1.22 (0.80–1.87) 1.11 (0.63–1.98)
ratio (adjusted*) Reference 1.21 (0.77–1.91) 1.04 (0.57–1.92)
or age, sex, race, education, income, congestive heart failure, hypertension, prior
oke, coronary artery disease, peripheral arterial disease, proteinuria, signiﬁcant kidney
, insulin use, and diabetes duration.
hemoglobin A1c.interaction between duration and age was small and
not statistically signiﬁcant (RERI: 0.34, 95% CI: 0.57
to 1.24). Because subjects with a prior stroke may be
at increased risk of incident ischemic stroke, we
performed analyses (both unstratiﬁed and stratiﬁed
by age) that excluded those with prior ischemic
stroke, and results were similar (data not shown).
Compared with nondiabetic patients, diabetic pa-
tients with an estimated duration >3 years had an
increased rate of ischemic stroke (adjusted HR: 1.62,
95% CI: 1.31 to 2.00), whereas diabetic patients with a
duration <3 years did not (adjusted HR: 0.90, 95% CI:
0.58 to 1.40) (Table 2). Results were similar when
using only baseline duration values. Analyses with a
3-level categorization of estimated diabetes duration
(<3, 3 to 8, and >8 years) showed a similarly
increased rate of ischemic stroke in both the 3 to 8
and >8 years categories (Online Table 1). At the time
of discharge, 52.4% of patients with estimated dia-
betes duration <3 years had major deﬁcits or worse
compared with 64.7% of patients with estimated
diabetes duration $3 years, although this difference
was not statistically signiﬁcant.
HbA1c AND ISCHEMIC STROKE. Using time-varying
HbA1c, there were 104 validated ischemic stroke
events during follow-up included in the HbA1c
analysis. The rate of ischemic stroke during
follow-up was 2.7 per 100 person-years (unadjusted
HR: 1.11, 95% CI: 0.63 to 1.98) in patients with
HbA1c $9.0% and 3.0 per 100 person-years (unad-
justed HR: 1.22, 95% CI: 0.80 to 1.87) in patients with
HbA1c between 7.0% and 8.9%, compared with a
rate of 2.5 per 100 person-years in patients with
HbA1c <7.0% (Table 3). In multivariable models
adjusting for stroke risk factors, insulin use, and
diabetes duration, neither poor glycemic control
(HbA1c $9.0%, adjusted HR: 1.04, 95% CI: 0.57 to
1.92) or moderately increased HbA1c (7.0% to 8.9%,
adjusted HR: 1.21, 95% CI: 0.77 to 1.91) were signiﬁ-
cantly associated with an increased rate of ischemic
stroke compared with patients who had HbA1c
<7.0%. There was similarly no signiﬁcant increase in
rate of ischemic stroke when only using baseline
HbA1c values. Results were similar when using
different rules for classifying time-varying HbA1c
values (i.e., valid for 6 months, valid for 1.5 years,
and assessed using linear interpolation) (Table 4).
Additionally, the results were similar in multivari-
able models that did not adjust for insulin use (data
not shown). Because the rate of ischemic stroke did
not vary signiﬁcantly by HbA1c level among diabetic
patients, we do not present analyses with nondia-
betic patients as the reference group. There was no
clear pattern in the proportion of patients discharged
TABLE 4 Association Between Time-Varying HbA1c Values and Incidence of Ischemic
Stroke Using Different Rules for Classifying Time-Varying HbA1c Values
HbA1c <7.0% HbA1c 7.0%–8.9% HbA1c >9.0%
6 months
Ischemic stroke events 32 33 7
Person-yrs 1,229.7 1,173.5 431.8
Rate, per 100 person-yrs 2.6 2.8 1.6
Hazard ratio (unadjusted) — 1.15 (0.70–1.88) 0.62 (0.27–1.41)
Hazard ratio (adjusted*) — 1.13 (0.67–1.92) 0.68 (0.29–1.62)
1.5 years
Ischemic stroke events 48 51 16
Person-yrs 1,905.7 1,684.9 660.0
Rate, per 100 person-yrs 2.5 3.0 2.4
Hazard ratio (unadjusted) — 1.24 (0.83–1.85) 0.96 (0.55–1.69)
Hazard ratio (adjusted*) — 1.24 (0.81–1.88) 0.95 (0.53–1.72)
Linear interpolation
Ischemic stroke events 55 59 20
Person-yrs 1,953.3 1,953.1 712.8
Rate, per 100 person-yrs 2.8 3.0 2.8
Hazard ratio (unadjusted) — 1.10 (0.77–1.59) 0.94 (0.57–1.57)
Hazard ratio (adjusted*) — 1.12 (0.76–1.63) 0.93 (0.55–1.58)
*Adjusted for age, sex, race, education, income, congestive heart failure, hypertension, prior thromboembolism,
coronary artery disease, peripheral arterial disease, proteinuria, signiﬁcant kidney dysfunction, insulin use, and
diabetes duration.
HbA1c ¼ hemoglobin A1c.
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245with major deﬁcits or worse by HbA1c category
(<7.0%: 64.6%, 7.0% to 8.9%: 52.9%, and $9.0%:
68.7%) and the observed differences were not signiﬁ-
cantly different.
INTERACTION BETWEEN HbA1c AND DURATION OF
DIABETES. Among diabetic patients, additive inter-
action between HbA1c and duration of diabetes was
assessed with HbA1c dichotomized at both 7.0%
(RERI: 0.16, 95% CI: 0.80 to 1.12) and 9.0% (RERI:
0.001, 95% CI: 1.32 to 1.33), and in both cases, the
magnitude of interaction was small.
DISCUSSION
Within a large, ambulatory cohort of adults with
atrial ﬁbrillation and diabetes, we found that longer
estimated duration of diabetes was strongly associ-
ated with an increase in adjusted rate of ischemic
stroke, while elevated HbA1c values were not
signiﬁcantly associated with an increase in ischemic
stroke among diabetic patients (Central Illustration).
The increased rate of ischemic stroke in those
who have had diabetes for an estimated $3 years
appeared to be independent of age as the associa-
tion was present in both older ($75 years) and
younger (<75 years) subjects.
Our results for diabetes duration are consistent
with prior research conducted within a general pop-
ulation of patients, which found an increased rate of
ischemic stroke as duration increased compared with
nondiabetic patients (9,10). However, our results for
HbA1c in diabetic patients with AF are not consistent
with prior research conducted in diabetic patients in
general. In our study, increased HbA1c did not have a
substantial effect on the rate of ischemic stroke,
whereas elevated HbA1c was signiﬁcantly associated
with ischemic stroke in predominantly non-AF pop-
ulations (11–13). A possible reason for HbA1c having
no association with ischemic stroke in diabetic pa-
tients with AF is the difference in the primary
mechanism for stroke in diabetic patients with and
without AF. Among patients with diabetes without
AF, stroke is often due to underlying atherosclerosis
(22,23). This mechanism may not be as important
among diabetic patients with AF, because the pri-
mary mechanism for ischemic stroke is atrio-embolic
(24). Duration of diabetes may be most important
among AF populations due to enhanced thrombin
generation, impaired ﬁbrinolysis with prolonged lysis
time, and unfavorably altered plasma ﬁbrin clot
structure, which may increase the risk of thrombotic
events (25,26).
Current stroke risk scoring systems for AF patients
include a diagnosis of diabetes mellitus as a strokerisk factor (7,8,18). Although the diagnosis of diabetes
has been shown to be a risk factor for stroke, the
magnitude of this association has varied among
different studies and has often been quite small. For
example, the association between diabetes and stroke
was small in the Swedish Atrial Fibrillation cohort
study (adjusted HR: 1.19) and the UK General Practice
Research Database (adjusted relative risk: 1.33),
whereas the association was larger in the ATRIA
cohort (HR: 1.57) and the AF Investigators pooled
analyses of warfarin trials (relative risk: 1.7)
(4,18,27,28). Our study suggests that stroke risk
schemes for AF patients could potentially be
improved by accounting for the patient’s diabetes
duration.
This study was strengthened by including a
large number of AF patients with diabetes from a
community-based cohort with comprehensive follow-
up. Furthermore, our large cohort is distinctive in
having information on HbA1c values and duration of
diabetes. The registry we utilized to identify patients
with diabetes has been demonstrated to be highly
sensitive (96% with self-reported diabetes from sur-
vey as gold standard) and speciﬁc (2% false positives)
(15). All events were adjudicated by physicians or
nurses using a standardized medical record review
protocol that minimizes errors in case ascertainment.
For both HbA1c and diabetes duration, we also were
CENTRAL ILLUSTRATION Assessing Which Characteristics of Diabetes Are Associated With Ischemic Stroke in
Patients With Atrial Fibrillation
Increased duration
of diabetes
Potential mechanisms:
Enhanced thrombin generation
Impaired fibrinolysis 
with prolonged lysis time
Patient with atrial fibrillation
and diabetes
Increased rate 
of ischemic stroke
No observed increased rate 
of ischemic stroke
Elevated hemoglobin A1c
(high blood glucose levels)
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246able to consider these variables as time-varying to
minimize misclassiﬁcation when assessing their
association with ischemic stroke.
STUDY LIMITATIONS. We are unable to separate type
1 and 2 diabetes. However, given the age of onset in
this population and the prevalence of type 2 diabetes,
we expect the vast majority are type 2 diabetic
patients. As this was a clinical practice-derived cohort,
there was no structured protocol to screen for dia-
betes, so there may be some misclassiﬁcation about
the actual duration of diabetes, especially given that
there is often a lag between diabetes onset and diag-
nosis (29). Although this study improves upon prior
studies by analyzing repeated measures of HbA1c, it is
possible that misclassiﬁcation and/or selection bias
may have occurred. Because not all patients received
regularly-spaced HbA1c laboratory monitoring, our
primary analyses allowed an HbA1c value to be valid
for up to 1 year. This approach was meant to minimize
misclassiﬁcation by using a single HbA1c value for an
overly long period of time. We examined the potential
for selection bias by comparing patients who did
versus did not go more than 1 year between HbA1c
measurements and found that having a gap between a
patient’s HbA1c measurements of $1 year was not
associated with HbA1c value, a ﬁnding that alleviatesconcerns about selection bias. Additionally, we per-
formed several sensitivity analyses using different
approaches for handling time-varying HbA1c values.
Considering an HbA1c value valid for 6 or 18 months
and using a linear interpolation approach (which did
not exclude person-time on the basis of gaps in mea-
surements) all had similar results to our primary
approach. Further, we also present analyses using
only baseline HbA1c values, and our results were
conﬁrmed. It remains possible that our follow-up
period of up to 7 years may not have been long
enough to observe an association between HbA1c and
thromboembolism. A ﬁnal concern is that there may
be residual confounding in these analyses. Con-
founding by age was of particular concern because
increased duration is correlated with increased age. In
addition to controlling for age in our multivariable
models, we also stratiﬁed our duration analyses by age
and found that duration of diabetes was associated
with ischemic stroke in both younger and older pa-
tients, although this was only statistically signiﬁcant
in older patients due to wide CIs.
CONCLUSIONS
Our study demonstrates that duration of diabetes is a
more important predictor of ischemic stroke than
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Among patients
with diabetes and AF, the duration of diabetes is a more impor-
tant predictor of ischemic stroke than glycemic control.
TRANSLATIONAL OUTLOOK: Future studies should address
whether incorporating the duration of diabetes in AF stroke risk
assessment tools improves prediction compared with the current
models that incorporate only the diagnosis of diabetes.
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247glycemic control in patients who have both diabetes
and atrial ﬁbrillation. Given the relatively small
association between the diagnosis of diabetes and
ischemic stroke in several published studies,
accounting for duration of diabetes may improve
stroke risk models for patients with AF.
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